Macrophage-EV miR-660 Drives Breast Cancer via KLHL21/NF-κB Axis

Study Background and Research Question

Breast cancer remains the most frequently diagnosed malignancy among women worldwide, with metastatic progression responsible for the majority of breast cancer-related deaths. Despite advances in adjuvant therapies, effective management of metastatic disease is still a major clinical challenge. Tumor-associated macrophages (TAMs) have emerged as pivotal regulators of the tumor microenvironment, influencing cancer cell proliferation, immune evasion, and dissemination. MicroRNAs (miRNAs) carried by extracellular vesicles (EVs) are increasingly recognized as key messengers in intercellular communication within tumors, modulating gene expression and cellular behavior. The central research question addressed in the reference study is how TAM-derived EV-enclosed miR-660 modulates breast cancer metastasis and what molecular mechanisms underlie this effect.

Key Innovation from the Reference Study

The innovative aspect of this work lies in the identification of a specific molecular axis—TAM-EV-shuttled miR-660 targeting KLHL21—which in turn regulates NF-κB p65 signaling. This mechanism provides a mechanistic explanation for how macrophage-derived EVs can promote breast cancer cell invasion and metastasis through non-coding RNA-mediated modulation of intracellular signaling pathways. The study bridges a crucial knowledge gap by connecting stromal cell-derived miRNAs, vesicle-mediated delivery, and the activation of pro-metastatic pathways in tumor cells.

Methods and Experimental Design Insights

The investigators employed a comprehensive, multi-level experimental strategy. Breast cancer tissues from patients were collected to isolate polarized TAMs and their secreted EVs. The expressions of miR-660, KLHL21, and NF-κB p65 were quantitatively measured using reverse transcription quantitative polymerase chain reaction (RT-qPCR), immunohistochemistry (IHC), and RNA-fluorescence in situ hybridization (RNA-FISH). Functional assays involved transfection of breast cancer cells with miR-660 mimics, inhibitors, and shRNA targeting KLHL21, followed by co-culture with TAMs or isolated EVs. Cancer cell invasion and migration were assessed through standard in vitro assays. The in vivo relevance was tested using a mouse model, where the impact of miR-660 and KLHL21 modulation on lymph node metastasis (LNM) was quantified in femoral and pulmonary tissues. Protein interactions were validated by co-immunoprecipitation (Co-IP) experiments.

Protocol Parameters

• TAM isolation: Fresh tumor tissues processed to isolate and polarize macrophages using specific surface markers.
• EV purification: Differential ultracentrifugation and filtration steps to obtain high-purity EVs from TAM culture supernatant.
• miR-660 manipulation: Transfection of breast cancer cells with synthetic miR-660 mimic or inhibitor; shRNA-mediated knockdown of KLHL21.
• Invasion/migration assays: Transwell systems with Matrigel for quantifying cellular migration and invasion after EV or TAM treatment.
• Mouse metastasis model: Tail vein injection of manipulated breast cancer cells, with subsequent assessment of metastatic foci by histology.

Core Findings and Why They Matter

The study demonstrated that breast cancer tissues and cell lines exhibited high miR-660 and low KLHL21 expression, correlating with poor overall survival. Mechanistically, TAM-derived EVs enriched in miR-660 are efficiently internalized by breast cancer cells. Once inside, miR-660 directly targets KLHL21 mRNA, decreasing its expression. KLHL21 normally binds to inhibitor kappa B kinase β (IKKβ), restraining NF-κB activation. Suppression of KLHL21 by miR-660 disrupts this interaction, leading to increased phosphorylation and nuclear translocation of NF-κB p65—a key driver of genes associated with tumor invasion and metastasis. Functionally, silencing KLHL21 or supplementing miR-660 via EVs markedly increased migration, invasion, and the number of metastatic foci in mouse models. These results position the TAM-EV-miR-660/KLHL21/NF-κB axis as a pivotal mechanism underpinning breast cancer metastatic progression and suggest new molecular targets for intervention.

Comparison with Existing Internal Articles

Several internal reviews have discussed the role of stromal-tumor signaling in breast cancer, but the present paper provides a unique mechanistic clarity. For example, the internal article "Macrophage-EV miR-660 Drives Breast Cancer Metastasis via KLHL21/NF-κB Axis" gives an overview of the same molecular pathway, emphasizing the translational potential of targeting EV-miR-660 for anti-metastatic strategies. This aligns well with the current study’s focus on intercellular vesicle-mediated communication and its role in driving aggressive cancer phenotypes. Additionally, the resource "(-)-Arctigenin: Workflow Optimization for NF-κB Pathway I..." highlights the utility of small molecule inhibitors such as (-)-Arctigenin in dissecting NF-κB signaling, further supporting the relevance of this pathway to experimental oncology.

Limitations and Transferability

While the study presents robust evidence linking TAM-derived EV-miR-660 to metastatic progression via the KLHL21/NF-κB axis, several limitations should be considered. The bulk of the functional data are derived from in vitro assays and murine models, which may not fully recapitulate the complexity of human metastatic disease. The heterogeneity among patient-derived TAMs and EVs, as well as potential off-target effects of miR-660 modulation, could influence clinical translatability. Furthermore, the selective targeting of the EV-miR-660/KLHL21/NF-κB pathway without affecting normal immune responses will require careful validation. These findings, while promising, represent an early step towards therapeutic exploitation and must be contextualized within broader tumor microenvironment research.

Why this cross-domain matters, maturity, and limitations

The elucidation of the TAM-EV-miR-660/KLHL21/NF-κB axis not only advances metastatic breast cancer biology but also underscores the broader significance of EV-mediated miRNA transfer in other inflammatory and neoplastic contexts. Given the centrality of NF-κB signaling in immune modulation, inflammation, and cancer, insights from this pathway may inform research into anti-inflammatory agents and targeted therapy development. However, the maturity of this bridge remains at the preclinical stage, requiring further validation in patient-derived models and clinical cohorts before translational application.

Research Support Resources

For researchers investigating NF-κB pathway modulation, metastasis, or anti-inflammatory strategies in the tumor microenvironment, tools such as (-)-Arctigenin (SKU N2399, APExBIO) may be valuable. (-)-Arctigenin is a bioactive small molecule characterized as both a MEK1 inhibitor and an iNOS expression inhibitor, offering mechanistic precision for dissecting the NF-κB and MAPK/ERK pathways in cellular models. Its established use in anti-inflammatory and antiviral compound research, together with high purity and robust solubility in DMSO, makes it suitable for advanced signaling studies. For detailed workflow optimization and troubleshooting strategies, the internal article "(-)-Arctigenin: Workflow Optimization for NF-κB Pathway I..." provides further guidance. As always, researchers should consult the product information for recommended handling and storage parameters.